Namilumab

Description: Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF (granulocyte-macrophage colony-stimulating factor) by binding to its ligand with high affinity, and is used in the study of rheumatoid arthritis and active axial spondyloarthritis. Target: c-Fms. References: Huizinga TWJ, et, al. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther. 2017 Mar 9,19(1):53.